Tags : (eravacycline)


Tetraphase Pharmaceuticals’ Xerava (eravacycline) Receives FDA’s Approval for Complicated Intra-Abdominal

Shots: The approval is based on the two P-III IGNITE study assessing Xerava (eravacycline, bid, IV) vs ertapenem & meropenem in patients with cIAI The study demonstrated a non-inferiority data clinical response vs ertapenem with well-tolerated results and achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates Xerava (eravacyclin, IV) is a […]Read More